Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
June 12 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, announced today that it has named Ben
Harshbarger as Senior Vice President, General Counsel. Mr.
Harshbarger brings to Catabasis more than 20 years of experience at
commercial-stage pharmaceutical and biotechnology companies.
“Ben brings to Catabasis extensive senior legal and compliance
experience in the pharmaceutical industry, including in product
launches, and the transition from pre-commercial to
commercial-stage. His deep expertise will be especially valuable in
the coming months as we prepare for top-line results from the Phase
3 PolarisDMD trial and the potential commercialization of
edasalonexent for the treatment of Duchenne muscular dystrophy,”
said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis.
“We are delighted that Ben has joined the team and will be
leveraging his operating and rare disease experience.”
“I am thrilled to be joining the Catabasis team as we work
towards making a new treatment option available to the Duchenne
community,” said Mr. Harshbarger. “Catabasis is preparing for the
potential future transition to a commercial organization, and I am
excited to join at such an important time.”
Mr. Harshbarger most recently served as the Interim Chief
Executive Officer and General Counsel at Novelion Therapeutics,
Inc., the parent company of Aegerion Pharmaceuticals, Inc. Prior to
that, he served in several legal roles at Aegerion Pharmaceuticals,
Inc., including as Deputy General Counsel, VP, EMEA Legal Counsel,
and Acting General Counsel and General Counsel. As Acting General
Counsel and General Counsel, he played a critical role in revamping
Aegerion’s compliance program. Mr. Harshbarger has also held senior
legal positions at Cubist Pharmaceuticals, Inc., Viacell, Inc. and
Biogen, Inc. Mr. Harshbarger holds his JD from Boston College Law
School, and his BA from the University of Richmond.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule designed to inhibit NF-kB that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. In DMD the loss of
dystrophin leads to chronic activation of NF-kB, which is a key
driver of skeletal and cardiac muscle disease progression. Our
ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy
and safety of edasalonexent for registration purposes.
Edasalonexent is also being evaluated in the GalaxyDMD open-label
extension trial. In our MoveDMD Phase 2 trial and open-label
extension, we observed that edasalonexent preserved muscle function
and substantially slowed disease progression compared to rates of
change in a control period, and significantly improved biomarkers
of muscle health and inflammation. The FDA has granted orphan drug,
fast track, and rare pediatric disease designations and the
European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s global Phase 3 PolarisDMD trial in DMD to evaluate the
efficacy and safety of edasalonexent for registration purposes, the
anticipated timing for top-line results, the potential timing for
the filing of an NDA, the Company’s planned transition to a
commercial-stage organization and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” “may” and
similar expressions, constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: risks and uncertainties related to the impact
of the COVID-19 pandemic, uncertainties inherent in the initiation
and completion of preclinical studies and clinical trials and
clinical development of the Company’s product candidates; whether
interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products; availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements; other matters that could affect
the availability or commercial potential of the Company’s product
candidates; and general economic and market conditions and other
factors discussed in the “Risk Factors” section of the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2020,
which is on file with the Securities and Exchange Commission, and
in other filings that the Company may make with the Securities and
Exchange Commission in the future. In addition, the forward-looking
statements included in this press release represent the Company’s
views as of the date of this press release. The Company anticipates
that subsequent events and developments will cause the Company’s
views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this release.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200612005011/en/
Catabasis Investor and Media
Contact Andrea Matthews Catabasis Pharmaceuticals, Inc. T:
(617) 349-1971 amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024